Undoubtedly, it is high time to take up the COVID-19 challenge and act aptly and promptly to prevent the exponential spread of the highly transmissible novel corona virus worldwide to encounter this ongoing deadly healthcare crisis. SARS-CoV2 virus has been demonstrated to have high transmissibility with humans worldwide being clueless on how to manage its spread. As we are all aware, prevention is always better than cure. So shouldn’t we proactively try to prevent the spread of novel corona virus by urgently putting in place interim guidelines for the monitored use of drugs having potential role as prophylactic agents against COVID-19 based on current available evidence rather than waiting for results of well controlled clinical trials on its role as prophylactic agent in preventing COVID infections as the delay could eventually prove counterproductive? With the novel coronavirus, we don’t have the luxury of waiting for those big, randomized control trials. We need to visit the data we have and more necessarily act logically. Efforts on developing neutralizing antibodies, vaccines and also trials on use of antivirals are ongoing; however, the availability and cost of such therapies will be a major deterrent for a developing country like India with over 1.3 billion naïve population.

References

1. Gautret., et al. “Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial”. International Journal of Antimicrobial Agents (2020).
2. Xue J., et al. “Chloroquine Is a Zinc Ionophore”. PLOS One 9.10 (2014): e0109180. 
3. Velthuis AJW., et al. “Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture”. PLOS Pathogen 6.11 (2010): e1001176.
4. Zhang L and Liu Y. “Potential interventions for novel coronavirus in China: A systematic review”. Journal of Medical Virology (2020).
5. Mahévas Matthieu., et al. “Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data”. British Medical Journal 369 (2020): m1844.
6. Mehra MR., et al. “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis”. The Lancet (2020). 
7. Vincent MJ., et al. “Chloroquine is a potent inhibitor of SARS coronavirus infection and spread”. Virology Journal 2 (2005): 69. 
8. Savarino A., et al. “New insights into the antiviral effects of chloroquine”. Lancet Infectious Diseases 6.2 (2006): 67-69.
9. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 395.10223 (2020): 497-506.
10. ICMR advisory on the use of Hydroxy-chloroquine (HCQ) as prophylaxis for SARS-CoV-2 infection. 
11. ICMR revised advisory on the use of Hydroxychloroquine (HCQ) as prophylaxis for SARS-CoV-2 infection (in supersession of previous advisory) (2020). 

Citation

Citation: Roosy Aulakh and CS Gautam. “Offering Hydroxychloroquine Prophylaxis to High Risk Corona Warriors: Ongoing Debate”. Acta Scientific Paediatrics 3.4 (2020): 40-42.

Copyright

Copyright: © 2020 Roosy Aulakh and CS Gautam. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.